TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2405108
Drug: rIL-2 via
Normalized name: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34)-peptide of parathyroid hormone (Homo sapiens parath
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIL-2 via splenic artery infusion
Study: 25301760
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm (long-term androgen deprivation therapy - ADT)
Study: 15380045
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (HRT), calcium, and vitamin D3
Study: 8217756
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream applied once daily for 40 weeks
Study: 3296861
Drug: Anticoagulants (phenprocoumon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulants (phenprocoumon or acenocoumarol)
Study: 3296861
Drug: Anticoagulants (phenprocoumon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulants (phenprocoumon or acenocoumarol) plus pentoxifylline (800-1200 mg/day)
Study: 3296861
Drug: Irregular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irregular treatment with various vasodilators (xanthinolnicotinate, naftidrofuryl, pyridylmethanol, etc.)
Study: 26708108
Drug: Placebo CBD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo CBD (0 mg)
Study: 26708108
Drug: CBD (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD (800 mg)
Study: 19920426
Drug: Ultrasound-guided interscalene
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided interscalene brachial plexus block with 10 mL of ropivacaine 0.75%
Study: 19920426
Drug: Nerve stimulation
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve stimulation interscalene brachial plexus block with 10 mL of ropivacaine 0.75%
Study: 10943872
Drug: Leflunomide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leflunomide (20 mg/day after a 3-day 100 mg/day loading dose)
Study: 8330603
Drug: Propofol 2.79
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.79 +/- 0.4 mg kg‐1 h‐1
Study: 8330603
Drug: Midazolam 0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.08 +/- 0.01 mg kg‐1 h‐1
Study: 8330603
Drug: Methohexitone 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methohexitone 1.8 +/- 0.2 mg kg‐1 h‐1
Study: 8330603
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no sedative agent)
Study: 3275752
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (CMF) with endocrine treatment (prednisone, oophorectomy)
Study: 7004624
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (CMF)
Study: 29401246
Drug: Lifastuzumab vedotin
Normalized name: Lifastuzumab vedotin
DrugBank: Lifastuzumab vedotin (DB15400)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifastuzumab vedotin (LIFA) 2.4 mg/kg, intravenously, every 3 weeks (Q3W)
Study: 29401246
Drug: Pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin (PLD) 40 mg/m2, intravenously, every 4 weeks (Q4W)
Study: 25306088
Drug: Oral olive
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral olive oil
Study: 25306088
Drug: Oral sunflower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sunflower oil (control)
Study: 9885327
Drug: Calcium carbasalate
Normalized name: carbasalate calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium carbasalate (equivalent to 900 mg aspirin) plus metoclopramide 10 mg (CM)
Study: 9885327
Drug: Ergotamine tartrate
Normalized name: Ergotamine Tartrate
DrugBank: Ergotamine (DB00696)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ergotamine tartrate 1 mg plus caffeine 100 mg (EC)
Study: 7102707
Drug: 3 percent
Normalized name: SALICYLIC ACID 3 g in 100 g TOPICAL GEL [Keralyt 3 PERCENT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 percent acyclovir ointment
Study: 29139301
Drug: Empagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (10 or 25 mg/day)
Study: 3519644
Drug: Bromocriptine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (5 mg/day)
Study: 15499953
Drug: 0.5 ml
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml 30% glucose by syringe
Study: 24649762
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (ESWT) as monotherapy, performed 1 time per week for 4 weeks.
Study: 24649762
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment (control group).
Study: 11052952
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (rhGH) with endurance training
Study: 6329863
Drug: Cereal-fibre-rich diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cereal-fibre-rich diet (42.4 g dietary fibre/6.7 MJ)
Study: 6329863
Drug: Diabetic diet
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetic diet (18.9 g dietary fibre/6.7 MJ)
Study: 27327855
Drug: Minimal-dose S-ketamine
Normalized name: (S)-(-)-ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal-dose S-ketamine (0.015 mg/kg/h infusion following a saline bolus)
Study: 25003802
Drug: Treatment 4
Normalized name: Acne Treatment 4 % - 5 % Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment 4 (transportation, screening, and prenatal, postpartum, and infant/toddler home visiting)
Study: 25003802
Drug: Combined control
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined control group (treatments 1 and 2)
Study: 25003802
Drug: Treatment 2
Normalized name: epoch Blemish Treatment 2 % Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment 2 (transportation plus developmental screening for infants and toddlers)
Study: 22775763
Drug: Antiplatelet agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet agent use
Study: 19574331
Drug: INTERCOM programme
Normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: INTERCOM programme (exercise training, education, nutritional therapy, smoking cessation counselling)
Study: 16343856
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg
Study: 20977368
Drug: Levofloxacin 750
Normalized name: levofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 750 mg
Study: 8562105
Drug: Propafenone (38
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (38 patients: 2 mg/kg over 15 min and then 10 mg/kg over the subsequent 24 h for non-converting)
Study: 602958
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of sisomicin
Study: 602958
Drug: Intermittent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent infusion of sisomicin
Study: 28531467
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine consumption (once daily for 1 month)
Study: 20520568
Drug: Fixed-combination latanoprost/timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-combination latanoprost/timolol (Xalacom)
Study: 7970848
Drug: Fluoroquinolone therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoroquinolone therapy
Study: 9776797
Drug: Self-monitoring tool
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-monitoring tool with monthly feedback of phosphorus levels and interdialytic weight gains
Study: 3043077
Drug: Plasma exchange
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma exchange with corticosteroids, cytotoxic drug, hemodialysis only when needed (Group I)
Study: 7402084
Drug: Nordiol (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nordiol (combination of ethinyl oestradiol and norgestrel)
Study: 30241872
Drug: Participants who
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants who did not receive information about their medications
Study: 30241872
Drug: Participants who
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants who integrated medication dosing into daily routines
Study: 27231800
Drug: Medication reconciliation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication reconciliation (intervention group)
Study: 25093754
Drug: Daily trimethoprim‐sulfamethoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily trimethoprim‐sulfamethoxazole (TS)
Study: 20574541
Drug: Monthly sulfadoxine‐pyrimethamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly sulfadoxine‐pyrimethamine (SP)
Study: 19068274
Drug: Intermittent FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent FOLFIRI chemotherapy
Study: 19068274
Drug: Continuous FOLFIRI
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous FOLFIRI chemotherapy
Study: 9835004
Drug: High-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose aprotinin (mean 5.2 x 10(6) KIU)
Study: 9835004
Drug: Low-dose aprotinin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose aprotinin (2 x 10(6) KIU)
Study: 9835004
Drug: Aprotinin-treated patients
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprotinin-treated patients (both doses)
Study: 2521409
Drug: Orthoclone OKT3
Normalized name: Orthoclone OKT3
DrugBank: Muromonab (DB00075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthoclone OKT3 for 14 days, azathioprine, and steroids
Study: 1080382
Drug: Phenylbutazone-prednisone combination
Normalized name: Phenylbutazone
DrugBank: Phenylbutazone (DB00812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylbutazone-prednisone combination
Study: 29911777
Drug: Herbal Extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal Extract Cream
Study: 25785703
Drug: 6% Carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% Carbohydrate (CHO) solution (15 g; 0.20 ± 0.02 g·kg(‐1))
Study: 25785703
Drug: 1.2% Caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2% Caffeine (CAF) solution (300 mg; 3.9 ± 0.3 mg·kg(‐1))
Study: 25785703
Drug: Carbohydrate with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate with caffeine (C + C) solution
Study: 23480456
Drug: M (PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: M (PCA regimen with morphine)
Study: 23480456
Drug: TM (PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: TM (PCA regimen with tenoxicam and morphine)
Study: 23480456
Drug: T+TM (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: T+TM (20 mg tenoxicam administered 30 minutes before wound closure in addition to the TM regimen)
Study: 10688810
Drug: Cs‐A3 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cs‐A3 (3 mg/kg/d)
Study: 10688810
Drug: Cs‐A1 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cs‐A1 (1 mg/kg/d)
Study: 1353088
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (untreated with topical antiseptics)
Study: 3922070
Drug: 20 per
Normalized name: evolocumab 420 per 3.5 ML Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 per cent lipid solution
Study: 3922070
Drug: Fat solutions
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat solutions alone or in combination with isotonic concentrations of dextrose
Study: 24114693
Drug: Fixed-time schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-time schedule of brief breaks (noncontingent escape) from ongoing dental treatment
Study: 15947609
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg twice daily for 28 days
Study: 8723848
Drug: Ketorolac 60
Normalized name: ketorolac 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 60 mg, administered intramuscularly 30 minutes before surgery
Study: 8723848
Drug: Saline (placebo),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (placebo), administered intramuscularly 30 minutes before surgery
Study: 23622906
Drug: BioFreedom drug-coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: BioFreedom drug-coated stent
Study: 9727544
Drug: Amlodipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (10 mg once daily)
Study: 23625113
Drug: Enalapril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (20 mg once daily)
Study: 3300755
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo followed at 35 min by i.v. diazepam 10 mg (Diazemuls)
Study: 30371148
Drug: MDMA 40
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA 40 mg (low dose)
Study: 24970869
Drug: Paricalcitol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paricalcitol (1 μg/d)
Study: 29880356
Drug: Calcitriol (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol (0.25 μg/d)
Study: 24363547
Drug: Cotrimoxazole Prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotrimoxazole Prophylactic Treatment (CPT)
Study: 15735111
Drug: Daily multiple
Normalized name: Daily Multiple Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily multiple micronutrient (DMM) supplementation
Study: 15735111
Drug: Weekly multiple
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly multiple micronutrient (WMM) supplementation
Study: 15735111
Drug: Daily iron
Normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iron (DI) supplementation
Study: 12057733
Drug: GnRHa (3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRHa (3.75 mg/4 weeks of triptorelin or 3.6 mg/4 weeks of goserelin)
Study: 15716202
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg po qhs for at least 4 weeks
Study: 11834123
Drug: High-dose glutamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose glutamine (0.3 g x kg(‐1))
Study: 11834123
Drug: Glycine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycine (0.3 g x kg(‐1))
Study: 7720759
Drug: felodipine (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: felodipine (any dose)
Study: 7720759
Drug: HCTZ (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCTZ (any dose)
Study: 30116855
Drug: Non-opioid medications
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-opioid medications (e.g., paracetamol, metamizole)
Study: 25102706
Drug: 0.125% levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% levobupivacaine (Group L) 80 ml
Study: 25102706
Drug: 0.09% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.09% NaCl (Group P) 80 ml
Study: 22183173
Drug: Dolutegravir 50
Normalized name: dolutegravir 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir 50 mg with moderate-fat meal
Study: 22183173
Drug: Dolutegravir 50
Normalized name: dolutegravir 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir 50 mg with high-fat meal
Study: 11122795
Drug: Primary therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary therapy
Study: 11122795
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with autologous hematopoietic support
Study: 8800784
Drug: Micronized 17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized 17 beta‐oestradiol (2 mg/day) continuously with dydrogesterone (10 mg/day) for the first 14 days of each cycle
Study: 31048187
Drug: Hydrocolloid dressings
Normalized name: Restore Extra Thin Hydrocolloid Dressings, 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocolloid dressings (VARIHESIVE® GEL CONTROL)
Study: 23161301
Drug: peginterferon alfa‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: peginterferon alfa‐2a (40KD; 180 μg/week)
Study: 15172894
Drug: Intranasal budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal budesonide for 2 weeks
Study: 8088139
Drug: 5% SLS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% SLS solution
Study: 8088139
Drug: 7.5% SLS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5% SLS solution
Study: 1234581
Drug: Variable insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Variable insulin doses
Study: 1234581
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of biguanides (metformin)
Study: 25745751
Drug: Cabergoline (Cb2)
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabergoline (Cb2) 0.5 mg oral per day for 8 consecutive days starting on the day of hCG administration
Study: 17031013
Drug: 5 microg
Normalized name: Digoxin 125 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 microg of vitamin D3 daily
Study: 17031013
Drug: 20 microg
Normalized name: Calcifediol 20 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 microg of vitamin D3 daily
Study: 28639987
Drug: Unfractioned heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfractioned heparin
Study: 3327683
Drug: Felodipine (0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (0.075 mg/kg)
Study: 29895045
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (34 children) participated in two gaming sessions (1.5 hours each) and an oral presentation about smoking and alcohol risks.
Study: 11134123
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg oral DHEA daily for 12 weeks
Study: 3023457
Drug: Topical alpha
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical alpha interferon gel (10^7 U) with nonoxynol 9 applied three times daily for 5 days
Study: 17584560
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Telmisartan and Ramipril
Study: 25302016
Drug: KM-023 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: KM-023 75 mg
Study: 25302016
Drug: KM-023 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: KM-023 150 mg
Study: 25302016
Drug: KM-023 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: KM-023 300 mg
Study: 25302016
Drug: KM-023 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: KM-023 600 mg
Study: 25302016
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of KM-023 75 mg
Study: 17631698
Drug: SR-CAP (sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR-CAP (sustained-release pellet formulation of diclofenac, 100 mg, once daily)
Study: 7859964
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of intravenous cefotaxime
Study: 2911170
Drug: Dexamethasone acetate
Normalized name: Dexamethasone Acetate
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone acetate 4 mg every six hours for six doses starting at exposure (2700 m)
Study: 2911170
Drug: Placebo every
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo every six hours for six doses starting at exposure (2700 m)
Study: 2911170
Drug: Dexamethasone acetate
Normalized name: Dexamethasone Acetate
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone acetate 4 mg every six hours for six doses starting at exposure (2050 m)
Study: 2911170
Drug: Placebo every
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo every six hours for six doses starting at exposure (2050 m)
Study: 21287560
Drug: Minocycline (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline (2 × 50 mg/d)
Study: 16814009
Drug: Cognitive-behavioral (CB)
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral (CB) treatment
Study: 12202014
Drug: 12-step treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-step treatment
Study: 15035271
Drug: Conventional-dose mannitol
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional-dose mannitol treatment (approximately 0.7 g/kg)
Study: 11318075
Drug: 85% NPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 85% NPH insulin and 15% regular human insulin (85/15)
Study: 11318075
Drug: 70% NPH/30%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70% NPH/30% regular human insulin (70/30)
Study: 11318075
Drug: 100% NPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% NPH insulin
Study: 3580233
Drug: morphine 10
Normalized name: morphine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 10 mg plus cisapride 10 mg
Study: 3580233
Drug: morphine 10
Normalized name: morphine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 10 mg plus cisapride 4 mg
Study: 31351965
Drug: GZ389988A (tropomyosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: GZ389988A (tropomyosin receptor kinase A inhibitor)
Study: 12628875
Drug: Amoxicillin-clavulanate for
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate for 6 weeks followed by nasal saline solution irrigation for 6 weeks
Study: 12628875
Drug: Nasal saline
Normalized name: Nasal Saline
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasal saline solution irrigation for 12 weeks (for children without chronic sinusitis)
Study: 9354220
Drug: Saline instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline instillation (1 mL/kg; maximum 10 mL) before catheter removal